Fundraising Fox
🦊/Companies
Sign in

Phathom Pharmaceuticals

Founded 2018 · 436 employees on LinkedIn · 3 known investors

Find your way into Phathom Pharmaceuticals

Phathom Pharmaceuticals is a pharmaceutical company that develops and markets prescription treatments, including VOQUEZNA (vonoprazan) for gastrointestinal conditions, in the U.S. market.

BiotechHealthtech

Founders & leadership

MB
Mr. BastaCEO

Investors · 3

Catalys PacificTokyo
Frazier Life SciencesPalo Alto
New Enterprise Associates (NEA)Menlo Park · $200K – $40M

In the news

Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Rating Upgraded by Leerink Partnersmarketbeat.com · Sep 2026Hsbc Holdings PLC Invests $7.70 Million in Phathom Pharmaceuticals, Inc. $PHATmarketbeat.com · Sep 2026Phathom at Cantor conference: growth, access and new uses By Investing.cominvesting.com · Sep 2026Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences | The Manila Timesmanilatimes.net · Sep 2026PHAT: Expanded Reflux Indication Will Support Anticipated 2026 Profitability Timelinesimplywall.st · Aug 2026Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here’s Whyfinance.yahoo.com · Mar 2026

Frequently asked questions

What does Phathom Pharmaceuticals do?
Phathom Pharmaceuticals is a pharmaceutical company that develops and markets prescription treatments, including VOQUEZNA (vonoprazan) for gastrointestinal conditions, in the U.S. market.
Who are Phathom Pharmaceuticals's investors?
Phathom Pharmaceuticals's investors include Catalys Pacific, Frazier Life Sciences, New Enterprise Associates (NEA).